For research and educational purposes only. Not medical advice.
Quercetin Reference
Educational, not medical advice reference for Quercetin: Longevity; regulatory status, evidence posture, source review, and schedule notes. Also known as 3,3…
Reference summary
Quercetin's role in the senolytic context is documented through the Justice 2019 EBioMedicine IPF pilot and Hickson 2019 EBioMedicine diabetic kidney disease pilot - both used quercetin as the dasatinib-partner senolytic agent in a D+Q combination. Quercetin's bioavailability as an oral flavonoid is limited (single-digit-percent oral absorption typical), which informed the rationale for combining it with dasatinib rather than using it alone. There is no large-scale human outcome trial of quercetin monotherapy for any indication.
Regulatory and posture
- Categories
- Longevity
- Aliases
- 3,3',4',5,7-pentahydroxyflavone, OTC dietary supplement flavonoid, Component of the D+Q senolytic combination
- Evidence posture
- human - Used in two small senolytic pilots in combination with dasatinib; no large-scale human outcome trial of quercetin monotherapy.
- Regulatory status
- Over-the-counter dietary supplement in the United States. Not FDA-approved as a drug for any indication. Off-label senolytic use in combination with dasatinib (D+Q) is investigational.
- Content review status
- research reference
Selected public sources
- PubMed: Justice et al. EBioMedicine 2019 - senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study (PMID 30616998)
- PubMed: Hickson et al. EBioMedicine 2019 - senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease (PMID 31542391)